Back to Screener

Healthcare

CTI BioPharma Corp.(CTIC)

Live Price

Offline

$9.10

+0.06% today

1Y Change

Window

No data

Market Cap
$1.20B
Revenue Growth
0.0%
EPS Growth
+28.8%
Dividend Yield
0.0%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

CTI BioPharma Corp. (CTIC) is a Healthcare stock with a market cap of $1.20B. The stock last traded around $9.10. Baseline metrics include revenue growth of 0.0%, EPS growth of +28.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +28.8%, free cash flow -25.1% with operating margin -147.9% and ROIC -84.2%. Valuation already assumes a fairly strong business story at price/sales 22.2. Stock Foundry combines CTIC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

-147.9% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2024 was reported on May 9, 2024, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is +28.8%, while operating margin sits near -147.9%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

CTIC

Normalized return

SPY

S&P 500

Excess Return

Relative to SPY

CTIC Max Drawdown

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CTIC and SPY.

Calendar-year return history is still loading or unavailable.
CT

Company Overview

CTI BioPharma Corp.

Last Updated
May 8, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
EV/EBITDA
Price/Sales
22.2
Price/Book

Growth

Revenue
0.0%
EPS
+28.8%
Free Cash Flow
-25.1%

Profitability

Gross Margin
93.5%
Operating Margin
-147.9%
Net Margin
-168.8%
ROE
1318.5%
ROIC
-84.2%

Balance Sheet

Debt/Equity
Current Ratio
1.23

Earnings Reports

📅 Last reportedMay 9, 2024
PeriodB/MEPSEPS ΔRevenueRev Δ
May 9, 24
Est
Est
Mar 4, 24
Est
Est
Nov 6, 23
Est
Est
Aug 14, 23
-0.21
Est -0.08
-162.5%
Est 26570.0B
May 15, 23
-0.10
Est -0.10
0.0%
24116.0B
Est 22950.0B
+5.1%
Mar 6, 23
-0.14
Est -0.09
-55.6%
21083.0B
Est 23760.0B
-11.3%
Nov 7, 22
-0.13
Est -0.15
+13.3%
18241.0B
Est
Aug 8, 22
-0.21
Est -0.20
-5.0%
12329.0B
Est
May 12, 22
-0.37
Est -0.35
-5.7%
2295.0B
Est 13000.0B
-82.3%
Dec 31, 21
-0.39
Est
Est
Nov 12, 21
-0.26
Est -0.22
-18.2%
Est 12400.0B
Aug 5, 21
-0.21
Est -0.20
-5.0%
Est
Jun 1, 21
-0.23
Est -0.20
-15.0%
Est
Mar 17, 21
-0.20
Est -0.16
-25.0%
0M
Est
Nov 10, 20
-0.15
Est -0.15
0.0%
Est
Aug 6, 20
-0.19
Est -0.12
-58.3%
Est 540.0B

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.